The Benchmark Company has recently reduced AbCellera Biologics Inc (ABCL) stock to Hold rating, as announced on August 20, 2024, according to Finviz. Earlier, on February 22, 2024 ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cigna (CI – Research Report), Quest Diagnostics (DGX – ...

Here's how you might feel the pinch from tariffs on Canadian good and services as they take effect this weekend.

The Stargate Project, a $500B initiative focused on artificial intelligence, lifted AI-driven biotech stocks this week while boosting an unlikely winner, Metagenomi (NASDAQ:MGX), which benefitted from ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ImmunoPrecise Antibodies (IPA – Research ...

During a speech at the White House on Tuesday, Ellison emphasized AI's ability to detect cancer early through blood tests and its crucial role in creating individualized vaccines rapidly. This ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Also, in news for AbbVie this week, AbCellera has expanded its existing partnership with the company to include the discovery of T-cell engagers (TCE) for oncology applications. Give your business an ...

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Twitter by Jack Prescott. In this article, we will summarize the bulls’ thesis on ABCL. AbCellera Biologics Inc. (ABCL)'s share ...

Investing.com - Abcellera Biologics (NASDAQ: ABCL) reported second quarter EPS of $-0.02, $0.11 better than the analyst estimate of $-0.13. Revenue for the quarter came in at... ByInvesting.com ...